SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.08+0.9%Dec 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (13576)10/28/2004 9:30:24 PM
From: Miljenko Zuanic   of 52153
 
<<Based on this data, they are having active discussions with FDA for: broader label since the current trial is for gleason less than 7, accelerated approval and using current study as post marketing are part of discussions, >>

So, now again they want to change PIII statistic, as (my speculation) G>7 show greater survival benefit than G<7. Wander, how many subgroup one can form from 127 pts, IF minimal number of subject in group is ½?

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News